Cited by 1,521HIV-related health complications and treatmentsHIV/AIDS drug development and treatmentLipoproteins and Cardiovascular Health

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Class of Antiretroviral Drugs and the Risk of Myocardial Infarction

Open access

The DAD Study Group·2007·New England Journal of Medicine

DOI 10.1056/nejmoa062744

Open this paper in CoChat — free account

Abstract

BACKGROUND: We have previously demonstrated an association between combination antiretroviral therapy and the risk of myocardial infarction. It is not clear whether this association differs according to the class of antiretroviral drugs. We conducted a study to investigate the association of cumulative exposure to protease inhibitors and nonnucleoside reverse-transcriptase inhibitors with the risk of myocardial infarction. METHODS: We analyzed data collected through February 2005 from our prospective observational study of 23,437 patients infected with the human immunodeficiency virus. The incidence rates of myocardial infarction during the follow-up period were calculated, and the associations between myocardial infarction and exposure to protease inhibitors or nonnucleoside reverse-transcriptase inhibitors were determined. RESULTS: Three hundred forty-five patients had a myocardial infarction during 94,469 person-years of observation. The incidence of myocardial infarction increased from 1.53 per 1000 person-years in those not exposed to protease inhibitors to 6.01 per 1000 person-years in those exposed to protease inhibitors for more than 6 years. After adjustment for exposure to the other drug class and established cardiovascular risk factors (excluding lipid levels), the relative rate of myocardial infarction per year of protease-inhibitor exposure was 1.16 (95% confidence interval [CI], 1.10 to 1.23), whereas the relative rate per year of exposure to nonnucleoside reverse-transcriptase inhibitors was 1.05 (95% CI, 0.98 to 1.13). Adjustment for serum lipid levels further reduced the effect of exposure to each drug class to 1.10 (95% CI, 1.04 to 1.18) and 1.00 (95% CI, 0.93 to 1.09), respectively. CONCLUSIONS: Increased exposure to protease inhibitors is associated with an increased risk of myocardial infarction, which is partly explained by dyslipidemia. We found no evidence of such an association for nonnucleoside reverse-transcriptase inhibitors; however, the number of person-years of observation for exposure to this class of drug was less than that for exposure to protease inhibitors.

Integrity signals

Registry

Crossref · 10.1056/nejmoa062744

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Declining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus Infection
Palella, F. J., Delaney, K. M., Moorman, A. C., Loveless, M. O., Fuhrer, J., Satten, G. A., Aschman, D. J., & Holmberg, S. D. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803263381301 · Cited by 9,393
Myocardial infarction and coronary deaths in the World Health Organization MONICA Project. Registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents.
Tunstall-Pedoe, H., Kuulasmaa, K., Amouyel, P., Arveiler, D., Rajakangas, A.-M., & Pająk, A. (1994) · Circulation · doi:10.1161/01.cir.90.1.583 · Cited by 2,260
CD4+ Count–Guided Interruption of Antiretroviral Treatment
The Strategies for Management of Antiretroviral Therapy (SMART) Study Group (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062360 · Cited by 2,250
Self-citation
Combination Antiretroviral Therapy and the Risk of Myocardial Infarction
El-Sadr, W. M., & The Data Collection On Adverse Events Of Anti-HIV Drugs (DAD) Study Group (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030218 · Cited by 1,677
Self-citation
Changing patterns of mortality across Europe in patients infected with HIV-1
Mocroft, A., Vella, S., Benfield, T., Chiesi, A., Miller, V., Gargalianos, P., Monforte, A. D., Yust, I., Bruun, J., Phillips, A. N., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)03201-2 · Cited by 1,269
Cardiovascular disease risk factors in HIV patients – association with antiretroviral therapy. Results from the DAD study
Friis‐Møller, N., Weber, R. K., Reiss, P., Thiébaut, R., Kirk, O., Monforte, A. D., Pradier, C., Morfeldt, L., Mateu, S., Law, M. G., et al. (2003) · AIDS · doi:10.1097/00002030-200305230-00010 · Cited by 1,076
Efavirenz plus Zidovudine and Lamivudine, Efavirenz plus Indinavir, and Indinavir plus Zidovudine and Lamivudine in the Treatment of HIV-1 Infection in Adults
Staszewski, S., Morales-Ramirez, J. O., Tashima, K. T., Rachlis, A., Skiest, D. J., Stanford, J., Stryker, R., Johnson, P. C., Labriola, D., Farina, D., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199912163412501 · Cited by 993
Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study
Ledergerber, B., Egger, M., Opravil, M., Telenti, A., Hirschel, B. J., Battegay, M., Vernazza, P., Sudre, P., Flepp, M., Furrer, H., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(99)01122-8 · Cited by 906
Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome
Grünfeld, C., Pang, M., Doerrler, W. T., Shigenaga, J. K., Jensen, P., & Feingold, K. R. (1992) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.74.5.1373735 · Cited by 845
Impact of HIV infection and HAART on serum lipids in men
Riddler, S. A. (2003) · JAMA · doi:10.1001/jama.289.22.2978 · Cited by 624

Flagged first, then by citations

Show all 26 references

Research works printed but not linked: 3

10.1210/jc.74.5.1045 · DOI
Phillips AN, Carr A, Neuhaus J, et al. Interruption of ART and risk of cardiovascular disease: findings from SMART. Presented at the 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, February 26, 2007. abstract. (Accessed March 29, 2007, athttp://www.retroconference.org/2007/abstracts/28863.htm.)
Sabin C, Morfeldt L, Friis-Møller N, et al. Changes over time in antiretroviral therapy (ART) use and risk factors for cardiovascular disease (CVD) in the D:A:D study. Presented at the 12th Conference on Retroviruses and Opportunistic Infections, Boston, February 25, 2005. abstract. (Accessed March 29, 2007, athttp://www.retroconference.org/2005/cd/abstracts/25243.htm.)

Sorted by citations

Items 901–999 of 999

Benchmarks of Diabetes Care in Men Living With Treated HIV-Infection: A Tertiary Center Experience
Fazekas, M., Tonks, K. T. T., & Samaras, K. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00634 · Cited by 9
AIDS at 40th: The progress of HIV treatment in Japan
Oka, S. (2022) · Global Health & Medicine · doi:10.35772/ghm.2021.01120 · Cited by 9
Lipid and Lipoprotein Profile in HIV-Infected Patients Treated with Lopinavir/Ritonavir as a Component of the First Combination Antiretroviral Therapy
Magenta, L., Dell‐Kuster, S., Richter, W. O., Young, J., Hasse, B. K., Flepp, M., Hirschel, B. J., Vernazza, P., Evison, J., Cavassini, M. L., et al. (2010) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2010.0207 · Cited by 9
A Study of Biological Markers in HIV Disease Progression and Management in yhe Highly Active Antiretroviral Therapy (HAART) Era
Kandi, V. (2013) · American Journal of Bioscience and Bioengineering · doi:10.11648/j.bio.20130102.11 · Cited by 9
Improved Measures of Quality of Life, Lipid Profile, and Lipoatrophy After Treatment Interruption in HIV-Infected Patients With Immune Preservation: Results of ACTG 5170
Skiest, D. J., Krambrink, A., Su, Z., Robertson, K. R., & Margolis, D. M. (2008) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e31818cde21 · Cited by 9
Other manifestations of HIV vasculopathy.
Naidoo, N. G., & Beningfield, S. J. (2009) · PubMed · Cited by 9
Variable endothelial cell function restoration after initiation of two antiretroviral regimens in HIV-infected individuals
Echeverría, P., Gómez‐Mora, E., Roura, S., Bonjoch, A., Puig, J., Pérez‐Álvarez, N., Bayés‐Genís, A., Clotet, B., Blanco, J., & Negredo, E. (2017) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx074 · Cited by 9
Evaluation of Vascular Event Risk while on Long-term Anti-retroviral Suppressive Therapy [EVERLAST]: Protocol for a prospective observational study
Sarfo, F. S., Nichols, M. G., Gebregziabher, M., Tagge, R., Asibey, S. O., Jenkins, C. M., & Ovbiagele, B. I. (2019) · eNeurologicalSci · doi:10.1016/j.ensci.2019.100189 · Cited by 9
Cardiovascular adverse events during treatment with darunavir-based regimens in an Italian observational study
Antinori, A., Rusconi, S., Gianotti, N., Bini, T., Mancusi, D., & Termini, R. (2019) · Drug Design Development and Therapy · doi:10.2147/dddt.s180981 · Cited by 9
Clinical and procedural characteristics of persons living with HIV presenting with acute coronary syndrome
Moran, C. A., Southmayd, G., Devireddy, C. M., Quyyumi, A. A., Ofotokun, I., Liberman, H. A., Jaber, W. A., & Sheth, A. N. (2019) · AIDS · doi:10.1097/qad.0000000000002393 · Cited by 9
Markers of subclinical atherosclerotic disease in HIV-infected individuals
Gupta, P. K., Gupta, M., Lal, A. K., Taneja, A. K., Taneja, R. S., & Rewari, B. B. (2018) · Journal of Virus Eradication · doi:10.1016/s2055-6640(20)30237-5 · Cited by 9
Implementation of Cholesterol-Lowering Therapy to Reduce Cardiovascular Risk in Persons Living with HIV
Wang, S. C., Kaur, G., Schulman‐Marcus, J., Purga, S. L., Mookherjee, S., Miller, C., Sidhu, M. S., & Rosenson, R. S. (2020) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-07085-8 · Cited by 9
Associations of gamma-glutamyl transferase with cardio-metabolic diseases in people living with HIV infection in South Africa
Nguyen, K. A., Peer, N., & Kengne, A. P. (2021) · PLoS ONE · doi:10.1371/journal.pone.0246131 · Cited by 9
So Pathogenic or So What?—A Brief Overview of SIV Pathogenesis with an Emphasis on Cure Research
Kleinman, A. J., Pandrea, I., & Apetrei, C. (2022) · Viruses · doi:10.3390/v14010135 · Cited by 11
The impact of SARS-CoV-2 treatment on the cardiovascular system: an updated review
Akkaif, M. A., Sha’aban, A., Cesaro, A., Jaber, A. A. S., Vergara, A., Yunusa, I. U., Jatau, A. I., Mohammed, M., Govindasamy, G. S., Al‐Mansoub, M. A., et al. (2022) · Inflammopharmacology · doi:10.1007/s10787-022-01009-8 · Cited by 9
Coronary Artery Disease in Persons With Human Immunodeficiency Virus Without Detectable Viral Replication
Knudsen, A. D., Fuchs, A., Benfield, T., Gerstoft, J., Køber, L., Trøseid, M., Kofoed, K. F., & Nielsen, S. D. (2023) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofad298 · Cited by 9
Immunological and Haematological Changes in HIV Infection
Mohamad, W. M. W., Rahman, W. S. W. A., Al-Salih, S. A. A., & Hussin, C. M. C. (2015) · InTech eBooks · doi:10.5772/61259 · Cited by 9
Switch to etravirine for HIV ‐positive patients receiving statin treatment: a prospective study
Ciaffi, L., Cavassini, M. L., Genné, D., Delhumeau, C., Spycher-Elbes, R., Hill, A. M., Wandeler, G., Fehr, J. S., Stoeckle, M. P., Schmid, P., et al. (2015) · European Journal of Clinical Investigation · doi:10.1111/eci.12464 · Cited by 9
Enfermedad arterial periférica asintomática estimada mediante el índice tobillo-brazo en pacientes con infección por el VIH: prevalencia y factores de riesgo asociados
Canalejo, E., Cabello, N., Perales, I., Hoz, S. A. D. L., & Purificación, A. S. (2011) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/j.eimc.2011.07.006 · Cited by 9
Reduced IgM levels and elevated IgG levels against oxidized low-density lipoproteins in HIV-1 infection
Yilmaz, A., Jennbacken, K., & Fogelstrand, L. (2014) · BMC Infectious Diseases · doi:10.1186/1471-2334-14-143 · Cited by 9
Left ventricular hypertrophy detected by echocardiography in HIV-infected patients
Pombo, M., Olalla, J., del Arco, A., Lima, J. D. L. T., Urdiales, D., Aguilar, A., Prada, J. L., García‐Alegría, J., & Ruiz‐Mateas, F. (2013) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2013.04.007 · Cited by 9
Prevalence and severity of ventricular dysfunction in patients with HIV-related pulmonary arterial hypertension
Dellegrottaglie, S., García‐Álvarez, A., Guarini, P., Filardi, P. P., Fuster, V., & Sanz, J. (2014) · Heart & Lung · doi:10.1016/j.hrtlng.2014.02.007 · Cited by 9
Epidemiology of Coronary Heart Disease in HIV Patients
Triant, V. A. (2014) · Reviews in Cardiovascular Medicine · Cited by 9
Antiretroviral treatment and time since HIV-1 diagnosis are associated with large artery stiffness in sub-Saharan African HIV-1 patients
Msoka, T. F., Guilder, G. P. V., Smulders, Y. M., van Furth, A. M., Bartlett, J. A., & van Agtmael, M. A. (2016) · Artery Research · doi:10.1016/j.artres.2016.09.002 · Cited by 9
Management of Long-Term Complications of HIV Disease: Focus on Cardiovascular Disease.
Currier, J. S. (2018) · Europe PMC (PubMed Central) · Cited by 9
Burden of arrhythmia in hospitalized HIV patients
Abudan, A. A., Vaidya, V. R., Tripathi, B., Noseworthy, P. A., DeSimone, D. C., Egbe, A., Arora, S., Sridhar, H., DeSimone, C. V., Mulpuru, S. K., et al. (2020) · Clinical Cardiology · doi:10.1002/clc.23506 · Cited by 9
Multidisciplinary collaborative integrated management of increasingly prominent HIV complications in the post‐cART era
Lin, L., & Li, T. (2020) · HIV Medicine · doi:10.1111/hiv.13022 · Cited by 9
Comparison of brachial and carotid artery ultrasound for assessing extent of subclinical atherosclerosis in HIV: a prospective cohort study
Odueyungbo, A. O., Smieja, M., Thabane, L., Smaill, F., Gough, K. A., Gill, M. J., Anderson, T. J., Elston, D., Smith, S., Beyene, J., et al. (2009) · AIDS Research and Therapy · doi:10.1186/1742-6405-6-11 · Cited by 9
Boosted protease inhibitor-based or nonnucleoside reverse transcriptase-based HAART: is there a best choice for antiretroviral-naive HIV-1 infected patients?
Cuzin, L., Allavena, C., Morlat, P., & Dellamonica, P. (2008) · PubMed · Cited by 9
Caring for AIDS Patients in the ICU
Masur, H. (2009) · CHEST Journal · doi:10.1378/chest.08-2199 · Cited by 9
Assessing Risk for Cardiovascular Disease in Patients With Human Immunodeficiency Virus
Sax, P. E. (2010) · Circulation · doi:10.1161/cir.0b013e3181d2c863 · Cited by 9
The next decade: cardiovascular risks, outcomes, prevention, and treatment in pediatric HIV infection
Miller, T. L. (2010) · Jornal de Pediatria · doi:10.2223/jped.1987 · Cited by 9
12-week Dolutegravir treatment marginally reduces energy expenditure but does not increase body weight or alter vascular function in a murine model of Human Immunodeficiency Virus infection
Kress, T. C., Ajala, P., Jordan, C. R., MINTZ, J. D., MacArthur, R. D., Kennard, S., Antonova, G. N., & de Chantemèle, E. J. B. (2024) · Vascular Pharmacology · doi:10.1016/j.vph.2024.107288 · Cited by 8
Abacavir/Lamivudine/Zidovudine Maintenance After Standard Induction in Antiretroviral Therapy-Naïve Patients: FREE Randomized Trial Interim Results
Sprenger, H. G., Langebeek, N., Mulder, P. G. H., ten Napel, C. H. H., Vriesendorp, R., Hoepelman, A. I. M., Legrand, J.-C., Koopmans, P. P., van Kasteren, M. E. E., Bravenboer, B., et al. (2010) · AIDS Patient Care and STDs · doi:10.1089/apc.2009.0236 · Cited by 8
Managing cardiovascular risk in people living with HIV in Asia – where are we now?
Choi, J. Y., Lui, G. C.-Y., Liao, C., & Yang, C. (2021) · HIV Medicine · doi:10.1111/hiv.13164 · Cited by 8
Leukocyte Count and Coronary Artery Disease Events in People With Human Immunodeficiency Virus: A Longitudinal Study
Avery, E. F., Kleynhans, J. N., Ledergerber, B., Schoepf, I. C., Thorball, C. W., Kootstra, N. A., Reiss, P., Ryom, L., Braun, D. L., Thurnheer, M. C., et al. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciad033 · Cited by 8
The Association of HIV-Specific Risk Factors with Cardiovascular Events in Addition to Traditional Risk Factors in People Living with HIV
Mavarani, L., Reinsch, N., Albayrak-Rena, S., Potthoff, A., Hower, M., Dolff, S., Schadendorf, D., Jöckel, K., Schmidt, B., Eßer, S., et al. (2023) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2023.0055 · Cited by 8
Racial Differences in Changes of Metabolic Parameters and Body Composition in Antiretroviral Therapy-Naive Persons Initiating Antiretroviral Therapy
Gibert, C. L., Shlay, J. C., Sharma, S., Bartsch, G. E., Peng, G., & Grünfeld, C. (2008) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e31818ce808 · Cited by 8
The Toxicogenetics of Antirretroviral Therapy: The Evil Inside
Gutiérrez, M. D. M., Mateo, M. G., Vidal, F., & Domingo, P. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711794088371 · Cited by 8
Comparative effectiveness of continuing a virologically effective first-line boosted protease inhibitor combination or of switching to a three-drug regimen containing either efavirenz, nevirapine or abacavir
Bommenel, T., Launay, O., Meynard, J., Gilquin, J., Katlama, C., Lascaux, A., Mahamat, A., Martinez, V., Pradier, C., Rouveix, É., et al. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr208 · Cited by 9
Evaluación del riesgo cardiovascular e intervención en los pacientes con VIH
Hernández, S., Vidal, M., & Pedrol, E. (2009) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/s0213-005x(09)73444-5 · Cited by 9
Maraviroc Intensification Improves Endothelial Function in Abacavir-Treated Patients, an Open-Label Randomized Cross-Over Pilot Study
Krikke, M., Tesselaar, K., Arends, J. E., Drylewicz, J., Otto, S. A., van Lelyveld, S. F. L., Visseren, F. L. J., & Hoepelman, A. I. M. (2016) · Infectious Diseases and Therapy · doi:10.1007/s40121-016-0115-0 · Cited by 8
Human Immunodeficiency Virus Infection And Hypertension. Is There a Connection?
Sanidas, E. A., Papadopoulos, D. P., Velliou, M., Tsioufis, K., Barbetseas, J. D., & Papademetriou, V. (2017) · American Journal of Hypertension · doi:10.1093/ajh/hpx208 · Cited by 8
Evaluation of antiretroviral effect on mitochondrial DNA depletion among HIV-infected patients in Bali
Masyeni, S., Sintya, E., Megawati, D., Sukmawati, N. M. H., Budiyasa, D. G. A., Aryastuti, S. A., Khairunisa, S. Q., Arijana, I. G. K. N., & Nasronudin, N. (2018) · HIV/AIDS - Research and Palliative Care · doi:10.2147/hiv.s166245 · Cited by 8
An Outlook on the Impact of HIV Infection and Highly Active Antiretroviral Therapy on the Cardiovascular System – A Review
Antony, I., Kannichamy, V., Banerjee, A., Gandhi, A. B., Subas, S. V., & Hamid, P. (2020) · Cureus · doi:10.7759/cureus.11539 · Cited by 8
Comparison of Tolerability and Impact on Metabolic Profiles of Antiretroviral Regimens Containing Darunavir/Ritonavir or Darunavir/Cobicistat in Romanian HIV Infected Patients
Marin, R.-C., Ţiţ, D. M., Săndulescu, O., Streinu‐Cercel, A., & BUNGAU, S. G. (2021) · Biomedicines · doi:10.3390/biomedicines9080987 · Cited by 8
Examining Depression as a Risk Factor for Cardiovascular Disease in People with HIV: A Systematic Review
Polanka, B. M., Gupta, S. K., So‐Armah, K., Freiberg, M. S., Zapolski, T. C. B., Hirsh, A. T., & Stewart, J. C. (2022) · Annals of Behavioral Medicine · doi:10.1093/abm/kaab119 · Cited by 8
Investigation of Causal Effects of Protein Biomarkers on Cardiovascular Disease in Persons With HIV
Reilly, C., Borges, Á. H., Baker, J. V., Safo, S. E., Sharma, S., Polizzotto, M. N., Pankow, J. S., Hu, X., Sherman, B. T., Babiker, A. G., et al. (2022) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiac496 · Cited by 8
Bictegravir/emtricitabine/tenofovir alafenamide plus doravirine in highly treatment-experienced men with multidrug-resistant HIV
Sterman, F. L., Lalezari, J. P., Kowalczyk, U. M., Main, D. W., Grant, E. M., Caro, L., Manning, C. M., & Burke, R. L. (2023) · AIDS · doi:10.1097/qad.0000000000003513 · Cited by 8
Documento de consenso sobre alteraciones metabólicas y riesgo cardiovascular en pacientes con infección por el virus de la inmunodeficiencia humana
(GEAM), D. L. S. D. P. N. S. E. S. (. Y. D. G. D. E. D. S. (. G. D. E. D. G. D. E. S. A. M. (2014) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/j.eimc.2014.06.006 · Cited by 8
HIV-induced immune activation - pathogenesis and clinical relevance. Summary of a workshop organised by the German AIDs Society (DAIG e.v.) and the ICH Hamburg, Hamburg, Germany, November 22, 2008
Stellbrink, H. J., Baldus, S. E., Behrens, G. M. N., Bogner, J. R., Harrer, T., Hoffmann, C., van Lunzen, J., Münch, J., Rácz, P., Scheller, C., et al. (2010) · European journal of medical research · doi:10.1186/2047-783x-15-1-1 · Cited by 9
A review of cardiovascular and renal function monitoring: a consideration of older adults with HIV
Vouri, S. M., Kebodeaux, C. D., Wilson, A., & Smith, D. (2013) · HIV/AIDS - Research and Palliative Care · doi:10.2147/hiv.s36311 · Cited by 8
Metabolic disorders induced by highly active antiretroviral therapy and their relationship with vascular remodeling of the brachial artery in a population of HIV-infected patients
Rossi, R., Nuzzo, A., Guaraldi, G., Squillace, N., Orlando, G., Esposito, R., Lattanzi, A., & Modena, M. G. (2009) · Metabolism · doi:10.1016/j.metabol.2009.02.026 · Cited by 8
The Deleterious Influence of Tenofovir-Based Therapies on the Progression of Atherosclerosis in HIV-Infected Patients
Aragonès, G., Pardo-Reche, P., Fernández-Sénder, L., Rull, A., Beltrán‐Debón, R., Rodríguez‐Gallego, E., Camps, J., Joven, J., & Alonso‐Villaverde, C. (2012) · Mediators of Inflammation · doi:10.1155/2012/372305 · Cited by 8
Cardiovascular disease associated with human immunodeficiency virus: A review
Costa, L. A., & Almeida, A. G. (2015) · Revista Portuguesa de Cardiologia (English Edition) · doi:10.1016/j.repce.2015.06.008 · Cited by 8
Abacavir/lamivudine plus darunavir/ritonavir in routine clinical practice: a multicentre experience in antiretroviral therapy-naive and -experienced patients
Podzamczer, D., Imaz, A., Pérez, I., Viciana, P., Valencia, E., Curto, J., Martin, T. J., Castaño, M., Rojas, J., Espinosa, N., et al. (2014) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dku157 · Cited by 8
Endothelial, Inflammatory, Coagulation, Metabolic Effects and Safety of Etravirine in HIV-Uninfected Volunteers
Gupta, S. K., Mi, D., Liu, Z., & Saha, C. (2011) · AIDS Patient Care and STDs · doi:10.1089/apc.2011.0011 · Cited by 8
The clinical implications of HIV infection and aging
John, M. D. V. (2016) · Oral Diseases · doi:10.1111/odi.12473 · Cited by 9
Antiretroviral Therapy for Human Immunodeficiency Virus Infection
Tsibris, A. M. N., & Hirsch, M. (2010) · Elsevier eBooks · doi:10.1016/b978-0-443-06839-3.00128-4 · Cited by 7
Risks associated with antiretroviral treatment for human immunodeficiency virus (HIV): qualitative analysis of social media data and health state utility valuation
Matza, L. S., Chung, K., Kim, K. J., Paulus, T. M., Davies, E. W., Stewart, K. D., McComsey, G. A., & Fordyce, M. W. (2017) · Quality of Life Research · doi:10.1007/s11136-017-1519-3 · Cited by 8
Serum suppression of tumorigenicity 2 level is an independent predictor of all-cause mortality in HIV-infected patients
Thiébaut, R., Hüe, S., Marec, F. L., Lelièvre, J., Dupon, M., Foucat, E., Lazaro, E., Dabis, F., Duffau, P., Wittkop, L., et al. (2017) · AIDS · doi:10.1097/qad.0000000000001628 · Cited by 8
The effect of switching protease inhibitors to raltegravir on endothelial function, in HIV-infected patients
Krikke, M., Tesselaar, K., van den Berk, G. E. L., Otto, S. A., Freriks, L. H., van Lelyveld, S. F. L., Visseren, F. L. J., Hoepelman, A. I. M., & Arends, J. E. (2018) · HIV Clinical Trials · doi:10.1080/15284336.2018.1455366 · Cited by 8
Recurrence after hospitalization for acute coronary syndrome among HIV ‐infected and HIV ‐uninfected individuals
Marcus, J. L., Hurley, L. B., Prasad, A., Zaroff, J. G., Klein, D., Horberg, M., Go, A. S., DeLorenze, G. N., Quesenberry, C. P., Sidney, S., et al. (2018) · HIV Medicine · doi:10.1111/hiv.12670 · Cited by 8
Association between statin use, atherosclerosis, and mortality in HIV-infected adults
Phan, B. A. P., Ma, Y., Scherzer, R., Deeks, S. G., & Hsue, P. Y. (2020) · PLoS ONE · doi:10.1371/journal.pone.0232636 · Cited by 8
The Effect of Foot Massage on Hemodynamic among Patients Admitted in to the Intensive Care Unit of General Public Hospital, Indonesia
Nyayu Nina Putri, C., Permana, B., & Lindayani, L. (2021) · KnE Life Sciences · doi:10.18502/kls.v6i1.8757 · Cited by 8
Comparable carotid intima-media thickness among long-term virologically suppressed individuals with HIV and those without HIV in Thailand.
Putcharoen, O., Pleumkanitkul, S., Chutinet, A., Vongsayan, P., Samajarn, J., Sophonphan, J., Kerr, S. J., Hiransuthikul, A., Siwamogsatham, S., Ruxrungtham, K., et al. (2019) · Europe PMC (PubMed Central) · Cited by 8
General Clinical Manifestations of Human Immunodeficiency Virus Infection (Including the Acute Retroviral Syndrome and Oral, Cutaneous, Renal, Ocular, Metabolic, and Cardiac Diseases)
Sterling, T. R., & Chaisson, R. E. (2010) · Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases · doi:10.1016/b978-0-443-06839-3.00121-1 · Cited by 8
Diagnosis and Management of Common Chronic Metabolic Complications in HIV-infected Patients
Bader, M. S., & Kelly, D. V. (2008) · Postgraduate Medicine · doi:10.3810/pgm.2008.11.1930 · Cited by 9
Determinants of Endothelial Function in Human Immunodeficiency Virus Infection: A Complex Interplay Among Therapy, Disease, and Host Factors
Mondy, K. E. (2008) · Journal of the CardioMetabolic Syndrome · doi:10.1111/j.1559-4572.2008.07599.x · Cited by 9
Lipid Abnormalities in Patients Infected With HumanImmunodeficiency Virus
Mikhail, N. E. (2008) · Endocrine Practice · doi:10.4158/ep.14.4.492 · Cited by 8
Prediction of Health Preference Values from CD4 Counts in Individuals with HIV
Isogai, P. K., Rueda, S., Rachlis, A., Rourke, S. B., & Mittmann, N. (2012) · Medical Decision Making · doi:10.1177/0272989x12453499 · Cited by 7
Sex-specific differences in treatment outcomes for patients with HIV and AIDS
Stenehjem, E. A., & Shlay, J. C. (2008) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/14737167.8.1.51 · Cited by 7
Considerations for the Long-Term Management of Women Living with HIV in Europe
Dominguez, S., Branco, T. L., & Haruperi, T. (2012) · Antiviral Therapy · doi:10.3851/imp2639 · Cited by 7
Drug combinations for HIV: what’s new?
Scourfield, A., Waters, L. J., & Nelson, M. R. (2011) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.11.125 · Cited by 7
Cardiovascular Disease in Patients with HIV
Knudsen, A., Kristoffersen, U. S., Kjær, A., & Lebech, A. (2012) · Future Virology · doi:10.2217/fvl.12.25 · Cited by 7
Angina pectoris in patients with HIV/AIDS: Prevalence and risk factors
Zírpoli, J. C., Lacerda, H. R., de Albuquerque, V. M. G., de Albuquerque, M. D. F. P. M., Miranda-Filho, D. D. B., Monteiro, V. S., de Barros, I. L., de Arruda, E. R., Montarroyos, U. R., & Ximenes, R. A. D. A. (2012) · The Brazilian Journal of Infectious Diseases · doi:10.1016/s1413-8670(12)70266-0 · Cited by 7
Toxicogenetics of Lopinavir/Ritonavir in Hiv-Infected European Patients
Aspiroz, E. L., Figueroa, S. E. C., Cruz, R., Hurtado, G. L. P., Martín, A. F., Hurlé, A. D.-G., Carracedo, Á., & The Team (2014) · Personalized Medicine · doi:10.2217/pme.14.7 · Cited by 7
Left Ventricular Dysfunction in Human Immunodeficiency Virus Infection
Cade, W. T. (2008) · Journal of the CardioMetabolic Syndrome · doi:10.1111/j.1559-4572.2008.07581.x · Cited by 7
Cardiovascular risks in Asian HIV-infected patients receiving boosted-protease inhibitor-based antiretroviral treatment
Ounjaijean, S., Kulprachakarn, K., Aurpibul, L., Kaewpoowat, Q., Boonyapranai, K., Chaiwarith, R., Arwon, S., Supparatpinyo, K., & Rerkasem, K. (2021) · The Journal of Infection in Developing Countries · doi:10.3855/jidc.12864 · Cited by 7
De novo electrocardiographic abnormalities in persons living with HIV
Knudsen, A. D., Graff, C., Nielsen, J. B., Thomsen, M. T., Høgh, J., Benfield, T., Gerstoft, J., Køber, L., Kofoed, K. F., & Nielsen, S. D. (2021) · Scientific Reports · doi:10.1038/s41598-021-00290-x · Cited by 7
The effect of changing to Bictegravir on lipids using real world data: A brief report
Heseltine, T., Hughes, E., Mathew, J., Murray, S. W., & Khoo, S. (2022) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13789 · Cited by 7
An update on the pharmacological strategies in the treatment of HIV-1-associated adipose redistribution syndromes
Mateo, G. M., Gutiérrez, M. D. M., Vidal, F., & Domingo, P. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.928694 · Cited by 7
Prevalence of Ischemic Heart Disease and Management of Coronary Risk in Daily Clinical Practice: Results from a Mediterranean Cohort of HIV-Infected Patients
Echeverría, P., Domingo, P., Llibre, J. M., Gutiérrez, M. D. M., Mateo, G. M., Puig, J., Bonjoch, A., Pérez‐Álvarez, N., Sirera, G., Clotet, B., et al. (2014) · BioMed Research International · doi:10.1155/2014/823058 · Cited by 7
Peripheral Arterial Disease and HIV-Positive Patients
Paraskevas, K. I., Katsiki, N., Tzovaras, A. A., Koupidis, S. A., & Mikhailidis, D. P. (2010) · Angiology · doi:10.1177/0003319710386473 · Cited by 7
Effects of pregnancy on endothelial function and cardiovascular disease risk in HIV-infected women
Luzi, K., Eckard, A. R., Lattanzi, A., Zona, S., Modena, M. G., Facchinetti, F., & Guaraldi, G. (2013) · Pregnancy Hypertension · doi:10.1016/j.preghy.2013.01.003 · Cited by 7
The Lopinavir/Ritonavir-Associated Rise in Lipids is not Related to Lopinavir or Ritonavir Plasma Concentration
Bierman, W. F. W., van Vonderen, M. G. A., Veldkamp, A. I., Burger, D. M., Danner, S. A., Reiss, P., & van Agtmael, M. A. (2011) · Antiviral Therapy · doi:10.3851/imp1824 · Cited by 7
Low-density lipoprotein and ritonavir: an interaction between antiretrovirals and lipids mediated by P-glycoprotein
Tempestilli, M., Elisei, F., Cimini, E., D’Avolio, A., Grassi, G., Nicastri, E., Narciso, P., Martini, F., Alonzi, T., & Pucillo, L. P. (2014) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dku066 · Cited by 7
Alcoholic Extract of Lotus Leaves Improves Lipid Profile in Rats with HIV Protease Inhibitor-induced Dyslipidemia
Su, Q., Lu, Z. Z., Deng, Q., & Wei, B. (2015) · West Indian Medical Journal · doi:10.7727/wimj.2014.373 · Cited by 7
Biochemical Parameters in Human Immunodeficiency Virus Disease Progression
Ramana, K. V., Rao, R., Venugopal, B., & Sanjeeva Rao, D. (2012) · Journal of Medical Microbiology & Diagnosis · doi:10.4172/2161-0703.1000103 · Cited by 7
Multiple coronary aneurysms in a young adult with acquired immunodeficiency syndrome
Heizer, J., Petersen, T. C., & Flemmer, M. C. (2016) · Oxford Medical Case Reports · doi:10.1093/omcr/omw036 · Cited by 7
Switching to Raltegravir From a Virologically Effective Boosted Protease Inhibitor Regimen: A Comparative Effectiveness Analysis From the French Hospital Database on HIV (FHDH-ANRS CO4)
Potard, V., Simon, A., Lacombe, J., Parienti, J., & Costagliola, D. G. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw498 · Cited by 7
Inhibition of osteoblast differentiation by ritonavir
Wakabayashi, Y., Yoshino, Y., Seo, K., Koga, I., Kitazawa, T., & Ota, Y. (2018) · Biomedical Reports · doi:10.3892/br.2018.1154 · Cited by 7
Switching from boosted PIs to dolutegravir in HIV-infected patients with high cardiovascular risk: 48 week effects on subclinical cardiovascular disease
Gonzalez‐Cordón, A., Assoumou, L., Camafort, M., Doménech, M., Guaraldi, G., Domingo, P., Rusconi, S., Raffi, F., Katlama, C., Masia, M., et al. (2020) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaa292 · Cited by 7
Self-citation
Contemporary role of nevirapine in HIV treatment.
Coster, L. O., & Kumar, P. N. (2012) · PubMed · Cited by 7
The Role of the Framingham Risk Score to Predict the Presence of Subclinical Coronary Atherosclerosis in Patients with HIV Infection
Rossi, R., Nuzzo, A., Guaraldi, G., Orlando, G., Squillace, N., Ligabue, G., Fiocchi, F., Girolamo, A. D., Romagnoli, R., & Modena, M. G. (2009) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e3181b18c19 · Cited by 7
Drug interactions between statins and antiretroviral agents
Burger, D. M., Stroes, E. S. G., & Reiss, P. (2008) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0b013e3282fbaa54 · Cited by 7
The SWITCHMRK studies: substitution of lopinavir/ritonavir with raltegravir in HIV-positive individuals
Cocohoba, J. M. (2009) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.09.110 · Cited by 7
Serum lipid profiles among patients initiating ritonavir-boosted atazanavir versus efavirenz-based regimens
Ganesan, A., Benning, L., Golub, E. T., Riddle, M. S., Crum‐Cianflone, N. F., Tasker, S. A., Jacobson, L. P., & Gange, S. J. (2009) · AIDS Research and Therapy · doi:10.1186/1742-6405-6-13 · Cited by 7
Treatment options for lipodystrophy in HIV-positive patients
Behrens, G. M. N. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.9.1.39 · Cited by 7

Authors: The DAD Study Group
Corresponding author: The DAD Study Group
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2007-04-26
Volume: 356
Issue: 17
Pages: 1723-1735
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa062744
OpenAlex: W1767400858
Cited by: 1,521
References: 26
Citations by year: 2026: 17 · 2025: 22 · 2024: 19 · 2023: 30 · 2022: 30 · 2021: 45 · 2020: 39 · 2019: 49 · 2018: 64 · 2017: 51 · 2016: 81 · 2015: 92 · 2014: 87 · 2013: 114 · 2012: 130
FWCI: 185.17
Type: journal article
Language: en
Open access: green
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Data Archiving and Networked Services (DANS) (submittedVersion)
Digital Access to Libraries (submittedVersion)
Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
UCL Discovery (University College London) (submittedVersion)
Pure Amsterdam UMC (submittedVersion)
Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
Columbia Academic Commons (Columbia University)
Funders: National Institute of Allergy and Infectious Diseases (U01AI046362, U01AI042170)
Topics: Health Sciences › Medicine › Infectious Diseases › HIV-related health complications and treatments
Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Keywords: myocardial infarction, antiretroviral drugs, protease inhibitors, non-nucleoside reverse transcriptase inhibitors, HIV infection, cardiovascular risk, dyslipidemia, serum lipids, drug exposure duration
MeSH terms: Adult, Female, Follow-Up Studies, Humans, Male, Middle Aged, Myocardial Infarction, Prospective Studies, Risk, HIV-1, HIV Infections, Incidence, Poisson Distribution, HIV Protease Inhibitors, Reverse Transcriptase Inhibitors, Observation, Anti-Retroviral Agents, Dyslipidemias

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Class of Antiretroviral Drugs and the Risk of Myocardial Infarction

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks